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Abstract The production of prostaglandins is regulated by
cyclooxygenases (COXs), which also have a role in tumour
development and progression in various human malignan-
cies, including cholangiocarcinoma. Limited information is
available of the correlation of COX-2 protein expression
and prognosis in intrahepatic cholangiocarcinoma (ICC).
The aim of the present study was to determine the clinical
significance of COX-2 expression in ICC. In addition the
correlation of COX-2 expression and apoptosis/prolifera-
tion was analysed. COX-2 expression was determined
immunohistochemically in 62 resected ICCs. Proliferation
was assessed using Ki67-immunohistochemistry, and apo-
ptosis was measured with the TdT-mediated dUTP nick-
end-labelling technique. COX-2 was identified as an
independent prognostic factor (P=0.028) in resected ICC
by survival analysis. High levels of COX-2 expression were
found to be associated both with reduced apoptosis and
increased proliferation of tumour cells. This study demon-
strates the independent prognostic value of the COX-2
expression in resected ICC, thus, offering a potential




Cholangiocarcinoma (CCC) is composed of cells resem-
bling those of bile ducts. CCC arises either from the
extrahepatic duct including the hilar bifurcation or from the
intrahepatic ducts. Intrahepatic cholangiocarcinoma (ICC)
is less frequent than extrahepatic bile duct carcinoma but
second among primary malignant liver tumours after
hepatocellular carcinoma. In Western countries, ICC
accounts for about 10% of the primary liver malignancies
with increasing incidence in the last two decades [24]. The
identification of patients with most aggressive ICC might
help to optimise surgical treatment and avoid unnecessary
surgical therapy. Therefore, it is desirable to identify
molecular markers that individually predict tumour behav-
iour and may facilitate an individualized therapy.
Among the potential prognostic parameters, cyclooxy-
genase (COX)-2 is of particular interest, as it may also offer
the option of treatment with nonsteroidal anti-inflammatory
drugs (NSAIDs) [15]. COXs regulate the synthesis of
prostaglandins and are, thus, the major target of NSAIDs.
Its two isoforms (COX-1 and COX-2) have different
expression patterns, with COX-1 being expressed in a
broad variety of tissues. COX-2 has been shown to
participate in tumour development and progression [11,
21]. Both elevated COX-2 messenger RNA (mRNA) and
protein levels were found to be raised in ICC [3, 9]. There
exist only few studies dealing with the potential prognostic
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Essen, Germanyvalue of the COX-2 expression. A small study with only 24
cases of CCC could not prove a significant association with
survival; however, this study did not discriminate between
extra- and intrahepatic cholangiocarcinoma [12]. Another
study on extrahepatic cholangiocarcinoma failed to de-
monstrate a correlation of the COX-2 expression and the
patients’ outcome in CCC [16]. In the present study, COX-
2 expression was determined by immunohistochemistry in
one of the largest contemporary series of consecutive
resected ICC. The findings were correlated with a broad
range of clinicopathological features. Recent observations
suggest that COX-2 overexpression may cause a prosta-
glandin E2-mediated inhibition of apoptosis in CCC.
Moreover, COX-2 overexpression was shown to increase
cell growth by the activation of E series of prostaglandins
(EP receptors) [8, 31]. Thus, apoptosis and proliferation
was determined in this series to monitor a putative
imbalance between cell death and cell proliferation induced
by COX-2 protein overexpression [26].
Materials and methods
Between August 1998 and August 2006, a total of 62
patients with a mean age of 58±11.5 years were available
for this study. The study comprised consecutive patients
who underwent surgery for liver resection. Patients solely
undergoing an explorative laparatomy without subsequent
resection were excluded from the study. Patients with hilar
cholangiocarcinoma, gallbladder carcinoma, or mixed
hepato/-CCC and liver cirrhosis were also excluded from
the study. The diagnosis of ICC was based on histology by
the examination of the resected liver specimen. The
tumours were classified according to the pathologic TNM
(pTNM) system (sixth edition) [28]. Detailed clinical data
was available including preoperative therapy, operative
details, and pathological findings including surgical radi-
cability, tumour staging, and clinical follow-up. One patient
suffered from primary sclerosing cholangitis without
cirrhosis; hepatolithiasis was not present in any case. Data
were completed by August 2006, and minimum follow-up
was every six months or until death. The median length of
the follow-up was 12 months.
Immunohistochemistry
Immunohistochemistry was performed with an automated
staining device (Dako Autostainer, Glostrup, Denmark).
Cyclooxygenase-2
In this study, a monoclonal rabbit anti-human COX-2
antibody (DCS, Hamburg, Germany) was used. Immuno-
histochemistry was performed on 5-μm-thick paraffin, and
antigen retrieval was carried out with 0.01-M citrate buffer
at pH 6.1 for 20 min in a hot water bath (95°C). The
primary antibody was incubated for 30 min at 1:250
dilution. Antibody demonstration was achieved using the
commercially available anti-mouse IgG detection kit (En-
Vision, DakoCytomation, Carpenteria, CA, USA) The
replacement of the primary antibodies by mouse immuno-
globin served as negative controls. Positive controls
(colorectal carcinoma) were included in each staining
series. In ICC, COX-2 was scored according to the amount
of positive stained tumour cells. One complete tumour slide
was examined for specific cytoplasmic COX-2 immuno-
staining. If none or less than 10% of the tumour cells
showed specific COX-2 immunostaining regardless of
staining intensity, the case was classified as negative. The
cases with 11–50% of the positively stained tumour cells
were classified as moderately positive and tumours with
more than 50% stained tumour cells as strongly positive.
Ki67 immunostaining and TdT-mediated dUTP nick-end
labelling
Ki67 immunohistochemistry was performed on 5-μm-thick
paraffin sections. Dewaxed and rehydrated sections were
incubated with hydrogen peroxide to block endogenous
peroxidase. After the antigen retrieval in a hot water bath,
the prediluted monoclonal anti-Ki67 antibody (Biogenex,
San Ramon, USA) was incubated for 30 min; antibody
demonstration was performed with the commercially
available anti-mouse IgG detection kit (EnVision, DakoCy-
tomation). The replacement of the primary antibodies by
mouse immunoglobin served as negative controls.
The growth fraction was defined as the percentage of
Ki67-positive, randomly chosen nuclei per 600 tumour
cells. In situ DNA fragmentation was established using the
terminal desoxyribonucleotide transferase TdT-mediated
dUTP nick-end-labelling technique (TUNEL) in paraffin-
embedded sections. We used ApoTag™ plus peroxidase in
situ apoptosis detection kit (Intergen). The staining proce-
dures were performed according the manufacturer’s recom-
mendations. The percentage of the stained apoptotic tumour
cells per 600 randomly chosen tumour cells was calculated.
To avoid miscounting of the necrotic cells, corresponding
H&E sections were examined.
Statistical analysis
COX-2 immunostaining was assessed by two of the authors
(K.J.S., H.R.) in a blind-trial fashion without knowledge of
the clinical outcome. In case of disagreement, slides were
re-evaluated by both investigators until agreement was
reached. All data were converted to a PC and statistically
136 Virchows Arch (2007) 450:135–141analysed using SPSS version 12 for Windows Statistical
Package for Social Sciences, Chicago, IL, USA.
The kappa coefficient of the inter-observer agreement was
calculated for the semiquantitative COX-2 immunostaining
results; the interpretation of the kappa value was performed
using the commonly cited scale of Landis and Koch [19]. The
interobserver agreement of COX-2 immunostaining was
substantial (kappa=0.73). Relationships between ordinal
parameters were investigated using the two-tailed χ
2 analysis
(or the Fisher’s exact test where patient numbers were
small). The relationship between categorical data (e.g. COX-
2) and numeric data (e.g. number on Ki-67 positive tumour
cells) was determined using the ANOVA test. The overall
survival (OS) curves were estimated using the Kaplan–Meier
method, and any differences in the survival curves were
compared by the log-rank test. For multivariate analysis, the
COX regression model was used. Overall, 95% confidence
intervals were used throughout.
Results
COX-2 immunohistochemistry
The COX-2 immunostaining was located in the cytoplasm
of epithelial cells. The plasma cells exhibited a positive
cytoplasmic immunostaining, serving as internal control.
Noncancerous intrahepatic bile duct epithelial cells next to
invasive cancer showed frequently a positive COX-2
immunoreactivity, whereas no COX-2 staining could be
detected distant from the tumour (Fig. 1). Hepatocytes near
and distant from ICC revealed a positive staining in all
cases. In all, 12 (19.4%) tumours were classified as
negative, 25 (40.3%) as moderately positive, and 25
(40.3%) as strongly positive. Epithelial tumour cells
exhibited a broad range of COX-2 immunoreactivity with
a complete lack of staining or a specific and strong granular
cytoplasmic COX-2 immunostaining (Fig. 2). COX-2
staining was not associated with any of the investigated
clinicopathological parameters (Table 1).
Clinical outcome by COX-2 expression
OS dependent on COX-2 expression was analysed using
Kaplan–Meier survival (n=62; p=0.036; Fig. 3). Patients
with a strong COX-2 expression exhibited a significantly
decreased OS, whereas patients classified as COX-2
negative revealed the most favourable OS. The unfavour-
able prognostic effect of tumours with elevated COX-2
protein expression remained in the subgroup of patients
with primarily R0-resected ICC (n=39; p=0.038).
The parallel univariate survival analysis showed a signif-
icant association of the resection status (p<0.001), multifocal
tumour growth (p=0.005), higher International Union
Fig. 1 Immunostaining for
COX-2 in noncancerous intra-
hepatic bile duct epithelial cells.
Whereas portal bile ducts distant
from the ICC consistently
lacked COX-2 immunostaining
(asterisk, left side), bile duct
epithelial cells (asterisk, right
side) adjacent to ICC (arrow)
exhibited cytoplasmic immuno-
reactivity of varying intensity.
Notice the COX-2 protein ex-
pression in normal hepatocytes.
Original magnification, ×400
Fig. 2 Representative COX-2
immunostaining results in ICC.
Missing COX-2 staining (left)i n
contrast to strong cytoplasmic
COX-2 immunoreactivity in
ICC tumour cells (right). Origi-
nal magnification, 400×. Inset:
positive control (colorectal car-
cinoma) with strong
immunostaining
Virchows Arch (2007) 450:135–141 137Against Cancer (UICC) stage (p=0.012), and vascular
invasion (p=0.011) with a reduced OS. Table 2 shows the
mean OS for all patients in the various subgroups.
To clarify the independent prognostic value of the COX-
2 expression in the patients with resected ICC, a multivar-
iate analysis of the relevant parameters was performed. The
COX regression analysis revealed the R-classification to be
the best prognostic factor for OS followed by the COX-2
expression (Table 3).
COX-2 and apoptosis/proliferation
There were significant lower mean numbers of apoptotic
tumour cells per 600 tumour nuclei in tumours with strong
COX-2 expression in contrast to tumours with moderate or
negative COX-2 immunoreactivity (Table 4). In contrast,
the proliferative activity increased in tumours with high
levels of COX-2, reflected by a higher mean value of
proliferating tumour cells. However, due to a substantial
overlap of values, statistical significance was not reached.
Discussion
CCC is a devastating cancer of the hepatic biliary tract. The
assessment of the individual prognosis of ICC patients may
be helpful to optimise decision making for surgical
treatment and avoid unnecessary surgical therapy. At
present, surgical therapy remains the only curative treat-
ment for ICC; thus, novel therapeutic strategies for this
aggressive cancer are necessary. This study on a large series
of 62 patients with resected ICC showed the independent
Table 1 COX-2 expression, demographic characteristics, and clinicopathological characteristics in 62 patients of the resected ICC
All COX-2 negative COX-2 moderate COX-2 strong P values
n (%) 62 12 (19.4) 25 (40.3) 25 (40.3)
Gender (male/female) 7/5 9/16 10/15 0.422
Mean age at diagnosis (y±SD) 58.8±11.5 52±12.1 60.4±9.8 60.6±11.8 0.067
Grading 0.612
G1 (n%) 2 (3.2) 0 (0) 2 (100) 0 (0)
G2 (n%) 41 (66.1) 7 (17.1) 15 (36.6) 19 (46.3)
G3 (n%) 19 (30.6) 5 (26.3) 8 (42.1) 6 (31.6)
UICC stage grouping 0.277
I 16 6 (37.5) 3 (18.8) 7 (43.8)
II 3 0 (0) 1 (33.3) 2 (66.7)
IIIA,B,C 38 5 (13.2) 19 (50) 14 (36.8)
IV 5 1 (20) 2 (40) 2 (40)
Staging 0.390
T1 (n,%) 21 7 (33.3) 5 (23.8) 9 (42.9)
T2 (n,%) 7 0 (0) 4 (57.1) 3 (42.9)
T3 (n,%) 28 4 (14.3) 13 (46.4) 11 (39.3)
T4 (n,%) 6 1 (16.7) 3 (50) 2 (33.3)
Lymph vessel infiltration 0.121
L0 47 7 (14.7) 18 (38.3) 22 (46.8)
L1 15 5 (33.3) 7 (46.7) 3 (20)
Blood vessel infiltration 0.916
V0 39 8 (20.5) 15 (38.5) 16 (41)
V1 23 4 (17.4) 10 (43.5) 9 (39.1)
Nodal status
a 0.281
0 37 10 (27) 15 (40.5) 12 (32.4)
1 21 2 (9.5) 10 (47.6) 9 (42.9)
Distant metastasis 0.999
No 57 11 (19.3) 23 (40.4) 23 (40.4)
Yes 5 1 (20) 2 (40) 2 (40)
Solitary tumour
b 32 7 (21.9) 11 (34.4) 14 (43.8) 0.545
Multifocal tumour 29 5 (17.2) 14 (48.3) 10 (34.5)
Tumour size 8.1 8.75±4.3 8.3±2.9 7.4±3.6 0.506
Resection status 0.627
R0 39 9 (32.1) 15 (38.5) 15 (38.5)
R1/2
c 23 3 (13) 10 (43.5) 10 (43.5)
P values were calculated using chi-square analysis and ANOVA for continuous variables
aData available for 58 patients;
bdata available for 61 patients;
c20 cases were classified R1, only 3 were R2
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COX-2 protein expression, thus, offering a potential
additional adjuvant therapeutic approach with COX-2
inhibitors. Elevated COX-2 expression was associated with
a marked reduced OS in multivariate analysis. The main
advantage of our study is the large number of patients (n=
62) in combination with a high homogeneity of this series
composed of consecutively resected ICC. A previous study
on extrahepatic cholangiocarcinoma failed to demonstrate a
relation of COX-2 expression with clinical outcome [16].
This suggests (genetic) differences depending on the site of
origin within the biliary tract. Mutations of the RAS and
TP53 genes are the most common genetic abnormalities
identified both in ICC and cancer of extrahepatic bile duct
(BDC) [13, 14, 16, 20, 29]. However, recent studies
disclosed genetic differences regarding p53 protein over-
expression among carcinomas of the proximal (ICC) and
distal bile ducts (BDC), indicating different patterns of the
inactivation of tumour-suppressor genes [1]. Because cell
line studies suggest COX-2 both as an effector and inhibitor
of the tumour suppressor p53 or DNA-damaging agents [4,
7], different genetic patterns in ICC and BDC, with varying
induction of COX-2 gene/protein expression, might explain
the diverse clinical impact of COX-2 in ICC and BDC.
A small study on 24 patients with CCC failed to show a
prognostic significance of the COX-2 expression [12].
However, the power of this study is limited due to two
reasons: (1) The authors did not discriminate between extra-
and intrahepatic cholangiocarcinoma, and (2) the statistical
power of a small series with 24 patients is very low.
However, Javle et al. [12] demonstrated in their study that
the median survival time of patients with low COX-2
expression was more than twice as high than that of patients
with high COX-2 expression. This finding is in accordance
with our results identifying COX-2 overexpression as a
predictor of reduced OS. Javle et al. found COX-2 to be
Fig. 3 Kaplan–Meier survival
curves in resected intrahepatic
cholangiocarcinoma in relation
to different COX-2 expression.
Tumours with elevated COX-2
levels exhibit a significantly
decreased overall survival (p=
0.036, Log Rank test)
Table 2 Mean overall survival in relation to different patient
subgroups







Moderate COX-2 expression 18.7
Strong COX-2 expression 11.4
Table 3 Multivariate COX regression analysis for overall survival in
62 patients with resected intrahepatic cholangiocarcinoma
HR (95% CI) P values
pTstage I–II/III–IV 1.63 (0.44–6.02) 0.465
UICC I–II, III–IV 1.20 (0.62–2.35) 0.589
Multifocality, solitary/multifocal 1.26 (0.41–3.89) 0.689
Resection status, R0/R1, R2
a 3.08 (1.27–7.44) 0.012
Vascular invasion, V0/V1 1.98 (0.88–4.41) 0.095
COX-2, negative/moderate/strong 1.07 (1.07–3.49) 0.028
aTwenty cases were classified R1, only three were R2
Virchows Arch (2007) 450:135–141 139expressed in all 24 ICC, whereas in our study, only 81% of
ICC exhibited an either moderate or strong COX-2 expres-
sion. Kim et al. [16] found COX-2 to be overexpressed in
only 52% of the examined extrahepatic cholangiocarcinomas.
These discrepancies are likely to be caused by differences in
antigen retrieval and varying scoring systems, emphasizing
the relevance of standardized protocols and immunoscores.
Previous studies suggest COX-2 overexpression as an
early carcinogenetic event in the human biliary tract and
pointed out that COX-2 expression was highest in more
differentiated CCC, whereas COX-2 expression decreased
with the loss of differentiation [5]. Our study did not reveal
a significantly increased COX-2 expression in tumours with
higher differentiation. Nevertheless, a detailed analysis of
our data rather supports this notion. The group of well and
moderately differentiated tumours exhibited the highest
amount of cancers classified as strongly COX-2 positive
(44.2%) in contrast to ICC with poor tumour differentiation
(31.6%). On the other hand, we found the lowest levels of
COX-2 expression to be more frequent in poorly differen-
tiated tumours (26.3%) in contrast to well or moderately
differentiated ICC (16.5%). The study by Kim et al. [16]o n
102 extrahepatic cholangiocarcinoma describes no signifi-
cant differences in terms of tumour differentiation. In the
light of these varying data, one should be careful not to
draw premature conclusions about the differential expres-
sion COX-2 protein in ICC.
The clinical conditions associated with ICC include
parasitic liver fluke infestations, hepatolithiasis, which is
frequently observed in clonorchiasis [10], nonbiliary cir-
rhosis, and primary sclerosing cholangitis [30]. It would be
interesting to compare the levels of COX-2 expression in
ICC with or without these established associated clinical
risk factors. However, our series is not suitable to answer
this question because all cases with liver cirrhosis,
regardless of its origin, were excluded from our study to
maintain the high homogeneity of our cohort and rule out
cirrhosis- related influence on patient survival. As a
consequence, this series comprises only one patient with
associated primary sclerosing cholangitis. Patients with
liver fluke infestations and associated hepatolithiasis were
not present in this series because our cohort is composed
from patients living in western Europe.
Interestingly, we found the up-regulation of COX-2
protein expression not only in cancerous epithelial cells but
also in noncancerous epithelial cells adjacent to invasive
cancer. Noncancerous epithelial cells distant from the ICC
lacked COX-2 immunostaining. This staining pattern is in
accordance with the results of Hayashi et al. [9]. The
elevated expression of COX-2 in bile duct epithelial cells
adjacent to invasive cancer is not surprising, as inflamma-
tion often accompanies invasive cancer and inflammatory
cytokines such as IL-1α [22], IL-1β [2], or TNF-α are
believed to induce COX-2 gene at the transcriptional level
[23]. We observed a constant positive specific immuno-
staining in normal hepatocytes regardless of the distance to
the ICC. This finding is in agreement with previous studies
documenting elevated COX-2 protein and mRNA expres-
sion in nontumourous liver [3, 17].
Against the background of NSAIDs, recent studies have
evaluated selective COX- inhibitors for their effect on CCC
cellscellgrowthandinvasioninvitroandinnudemice[6, 18,
27, 32, 33]. The treatment with COX-2 inhibitors resulted in
induced apoptosis and inhibited proliferation. The mecha-
nisms by which COX-2 contributes to the poor prognosis in
variety of human cancers have not been completely
elucidated yet. COX-2 has been shown to contribute to both
tumourigenesis and the malignant phenotype of tumour cells
by different mechanisms, including (1) the inhibition of
apoptosis by the activation of the PI3-Kinase/Akt pathway
and increased production of PGE2, leading to increased
expression of Bcl-2 and attenuation of nitric oxide signal-
ling, (2) increased angiogenesis by increased PGE2 produc-
tion with subsequent vascular endothelial growth factor
production, (3) increased invasiveness by the overexpression
of CD44, and (4) increased cell growth by the activation of
EP receptors [8, 31]. The above mentioned effect of COX-2
overexpression on apoptosis and proliferation can be
confirmed in our study. COX-2 over-expressing ICC
revealed a significantly decreased apoptosis and a higher
mean value of proliferating tumour cells, although the latter
finding did not reach statistical significance. This finding
suggests an impaired balance between cell loss and cell gain,
resulting in a shift towards tumour net tumour growth due to
increased apoptosis. The observed decrease of apoptosis in
COX-2 overexpressing ICC might be due to the PGE2-
mediated induction of the antiapoptotic protein Bcl-2 and
increased NFκB transcriptional activity, which is a key
antiapoptotic mediator [25, 26].
In conclusion, this study demonstrates the independent
prognostic value of immunohistochemical COX-2 protein
Table 4 Apoptosis (TUNEL) and proliferative activity (Ki67) in



















9.74±7.37 8.55±8.41 9.99±7.34 0.486
P values were calculated using ANOVA for continuous variables
140 Virchows Arch (2007) 450:135–141expression in resected ICC, thus, offering a potential
additional adjuvant therapeutic approach with COX-2 inhib-
itors and facilitating an optimised therapeutic strategy. Our
results suggest that COX-2 overexpression causes a shift
towards increased tumour cell proliferation and decreased
apoptosis contributing to the unfavourable clinical course.
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